Kiyoto Tsuchiya

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6335602/publications.pdf

Version: 2024-02-01

40 papers	1,301 citations	430754 18 h-index	360920 35 g-index
42 all docs	42 docs citations	42 times ranked	1753 citing authors

#	Article	IF	Citations
1	Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene, 2021, 766, 145145.	1.0	68
2	Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Scientific Reports, 2021, 11, 5563.	1.6	42
3	A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators. Frontiers in Microbiology, 2021, 12, 636276.	1.5	6
4	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. Journal of Infection and Chemotherapy, 2021, 27, 1063-1067.	0.8	9
5	N -(4-Hydroxyphenyl) Retinamide Suppresses SARS-CoV-2 Spike Protein-Mediated Cell-Cell Fusion by a Dihydroceramide Î”4-Desaturase 1-Independent Mechanism. Journal of Virology, 2021, 95, e0080721.	1.5	6
6	A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents inÂvitro. Cell Reports Methods, 2021, 1, 100122.	1.4	9
7	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. Scientific Reports, 2021, 11, 22848.	1.6	57
8	Fullâ€genome analysis of hepatitis C virus in HIVâ€coinfected hemophiliac Japanese patients. Hepatology Research, 2020, 50, 763-769.	1.8	1
9	Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production. Viruses, 2020, 12, 355.	1.5	9
10	Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 350-357.	0.9	8
11	Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase Câ€“induced HIV latency reversal. Journal of Biological Chemistry, 2019, 294, 116-129.	1.6	31
12	Highâ€performance liquid chromatographyâ€“tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples. Biomedical Chromatography, 2018, 32, e4058.	0.8	16
13	Assessment of HIV prevalence among MSM in Tokyo using self-collected dried blood spots delivered through the postal service. BMC Infectious Diseases, 2018, 18, 627.	1.3	25
14	Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. Frontiers in Microbiology, 2018, 9, 2022.	1.5	39
15	Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients. Transplantation Direct, 2017, 3, e151.	0.8	21
16	High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenetics and Genomics, 2017, 27, 416-419.	0.7	21
17	Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors. PLoS ONE, 2017, 12, e0177033.	1.1	10
18	The second molecular epidemiological study of HIV infection in Mongolia between 2010 and 2016. PLoS ONE, 2017, 12, e0189605.	1.1	7

#	Article	IF	Citations
19	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 11-14.	0.9	14
20	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Journal of Antimicrobial Chemotherapy, 2016, 71, 2760-2766.	1.3	6
21	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. Journal of Antimicrobial Chemotherapy, 2014, 69, 3320-3328.	1.3	15
22	Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 484-486.	0.9	14
23	Sphingomyelin Synthase 2, but Not Sphingomyelin Synthase 1, Is Involved in HIV-1 Envelope-mediated Membrane Fusion. Journal of Biological Chemistry, 2014, 289, 30842-30856.	1.6	26
24	Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochemical and Biophysical Research Communications, 2013, 439, 221-227.	1.0	45
25	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. Clinical Infectious Diseases, 2013, 57, 1051-1055.	2.9	22
26	Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. Scientific Reports, 2013, 3, 2389.	1.6	18
27	Single Nucleotide Polymorphisms in ABCC2 Associate With Tenofovir-Induced Kidney Tubular Dysfunction in Japanese Patients With HIV-1 Infection: A Pharmacogenetic Study. Clinical Infectious Diseases, 2012, 55, 1558-1567.	2.9	72
28	Identification of a Current Hot Spot of HIV Type 1 Transmission in Mongolia by Molecular Epidemiological Analysis. AIDS Research and Human Retroviruses, 2011, 27, 1073-1080.	0.5	11
29	Allele and Genotype Frequencies ofCytochrome P450 2B6Gene in a Mongolian Population. Drug Metabolism and Disposition, 2009, 37, 1991-1993.	1.7	17
30	High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007. International Journal of STD and AIDS, 2009, 20, 391-394.	0.5	18
31	Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition. Journal of Molecular Biology, 2008, 381, 956-974.	2.0	59
32	Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26. Clinical Infectious Diseases, 2007, 45, 1230-1237.	2.9	210
33	Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir,) Tj ETQq1 1 0.784314 rgBT /Ove transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. Biomedical Chromatography, 2006, 20, 28-36.	0.8	29
34	Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications, 2004, 319, 1322-1326.	1.0	257
35	â€œAll-in-One Assayâ€, a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations. Journal of Virological Methods, 2003, 111, 43-53.	1.0	6
36	Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naÄ±Ì^ve patients treated with NFV-containing regimens in an HIV clinic cohort. Journal of Clinical Virology, 2003, 27, 252-262.	1.6	2

#	Article	IF	Citations
37	Isolation and Molecular Characterization of a Nelfinavir (NFV)-Resistant Human Immunodeficiency Virus Type 1 That Exhibits NFV-Dependent Enhancement of Replication. Journal of Virology, 2003, 77, 318-327.	1.5	9
38	Emergence of Protease Inhibitor Resistanceâ€“Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 1-6.	0.9	43
39	Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. Aids, 2001, 15, 1183-1184.	1.0	14
40	A Widely-Distributed Hiv-1 Provirus Elimination Assay to Evaluate Latency-Reversing Agents in Vitro. SSRN Electronic Journal, 0, , .	0.4	0